Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Multicenter Study

Review

Clinical Trial, Phase III

Clinical Trial, Phase II

Clinical Trial, Phase I

Observational Study

Research Support, N.I.H., Extramural

Clinical Trial

Meta-Analysis

Case Reports

Comparative Study

Systematic Review

Evaluation Study

Network Meta-Analysis

Publication Year

From

Quick links

Individual year

2025

2024

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Lactams, Macrocyclic""[mesh_terms]

62 Results

Searching titles within these results

Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells.

Grzegorz Litwinienko, Maciej Wnuk, Tomasz Szmatoła, Michał Żebrowski, Anna Lewińska, Dominika Błoniarz, Susel Del Sol-Fernández, Julia Słaby, Pablo Martínez-Vicente, María Moros

ACS biomaterials science & engineering 2025;11(1):280-297

Free Full Text

Abstract

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, Isabelle Gaultier, Tatyana Dekhtyar, Liangjun Lu, Thomas Reisch, Michelle Irvin, Todd Hopkins, Ron Pithawalla, Timothy Middleton, Teresa Ng, Keith McDaniel, Yat Sun Or, Rajeev Menon, Dale Kempf, Akhteruzzaman Molla, Christine Collins

Antimicrobial agents and chemotherapy 2015;59(2):988-97

Free Full Text

Abstract

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

William K Oh, Matthew D Galsky, Walter M Stadler, Sandy Srinivas, Franklin Chu, Glenn Bubley, J Goddard, Joi Dunbar, Robert W Ross

Urology 2011;78(3):626-30

Free Full Text

Abstract

Identification of a biosynthetic gene cluster for the polyene macrolactam sceliphrolactam in a Streptomyces strain isolated from mangrove sediment.

Zhen Jie Low, Li Mei Pang, Yichen Ding, Qing Wei Cheang, Kim Le Mai Hoang, Hoa Thi Tran, Jinming Li, Xue-Wei Liu, Yoganathan Kanagasundaram, Liang Yang, Zhao-Xun Liang

Scientific reports 2018;8(1):1594

Free Full Text

Abstract

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.

Noriyuki Akutsu, Shigeru Sasaki, Takeshi Matsui, Hirofumi Akashi, Kazuhiko Yonezawa, Keisuke Ishigami, Masayuki Tsujisaki, Hiroyuki Isshiki, Atsushi Yawata, Satoshi Yamaoka, Toshihiro Ban, Takeya Adachi, Seiya Nakahara, Hideyasu Takagi, Kohei Nakachi, Katsunori Tanaka, Takehiro Hirano, Itaru Yamamoto, Hiroyuki Kaneto, Kohei Wagatsuma, Yasunao Numata, Hiroshi Nakase

Internal medicine (Tokyo, Japan) 2021;60(21):3369-3376

Free Full Text

Abstract

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.

Miao Miao, Xixi Jing, Erik De Clercq, Guangdi Li

Drug design, development and therapy 2021;14():2759-2774

Free Full Text

Abstract

Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.

Chiara Braconi, Fanyin Meng, Erica Swenson, Lyudmyla Khrapenko, Nianyuan Huang, Tushar Patel

Cancer 2009;115(16):3738-48

Free Full Text

Abstract

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.

Preethi Krishnan, Tami Pilot-Matias, Gretja Schnell, Rakesh Tripathi, Teresa I Ng, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Lois Larsen, Federico J Mensa, Christine Collins

Antimicrobial agents and chemotherapy 2019;62(10):e01249-18

Free Full Text

Abstract

Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.

Thitiya Boonma, Bodee Nutho, Nitchakan Darai, Thanyada Rungrotmongkol, Nadtanet Nunthaboot

Journal of biomolecular structure & dynamics 2022;40(12):5283-5294

Full Text

Abstract

Strong epistatic interactions within a single protein.

Mariona Parera, Miguel Angel Martinez

Molecular biology and evolution 2015;31(6):1546-53

Full Text

Abstract

Heat shock protein 90 inhibitors reduce trafficking of ATP-gated P2X1 receptors and human platelet responsiveness.

Ulyana Lalo, Sarah Jones, Jonathan A Roberts, Martyn P Mahaut-Smith, Richard J Evans

The Journal of biological chemistry 2012;287(39):32747-54

Free Full Text

Abstract

Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.

Peter N Morcos, Linda Chang, Mercidita Navarro, Diana Chung, Patrick F Smith, Barbara J Brennan, Jonathan Q Tran

International journal of clinical pharmacology and therapeutics 2014;52(2):103-11

Full Text

Abstract

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.

Adolfo de Salazar, Julia Dietz, Velia Chiara di Maio, Johannes Vermehren, Stefania Paolucci, Beat Müllhaupt, Nicola Coppola, Joaquín Cabezas, Rudolf E Stauber, Massimo Puoti, Juan Ignacio Arenas Ruiz Tapiador, Christiana Graf, Marianna Aragri, Miguel Jimenez, Annapaola Callegaro, Juan Manuel Pascasio Acevedo, Manuel Alberto Macias Rodriguez, Jose Miguel Rosales Zabal, Valeria Micheli, Miguel Garcia Del Toro, Francisco Téllez, Federico García, Christoph Sarrazin, Francesca Ceccherini-Silberstein

The Journal of antimicrobial chemotherapy 2021;75(11):3349-3358

Full Text

Abstract

Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.

Fred Poordad, RuiSarmento E Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Douglas Dieterich, Rui Tato Marinho, Armando Carvalho, Asma Siddique, Yiran Bonnie Hu, Mariem Charafeddine, Mark Bondin, Nader Khan, Daniel E Cohen, Franco Felizarta

Journal of viral hepatitis 2021;27(5):497-504

Full Text

Abstract

Cystein cathepsin and Hsp90 activities determine the balance between apoptotic and necrotic cell death pathways in caspase-compromised U937 cells.

Gergely Imre, Zsuzsanna Dunai, Istvan Petak, Rudolf Mihalik

Biochimica et biophysica acta 2007;1773(10):1546-57

Free Full Text

Abstract

Results: 1 – 15 / 62

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Lactams, Macrocyclic""[mesh_terms]

Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells.

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Identification of a biosynthetic gene cluster for the polyene macrolactam sceliphrolactam in a Streptomyces strain isolated from mangrove sediment.

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.

Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.

Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.

Strong epistatic interactions within a single protein.

Heat shock protein 90 inhibitors reduce trafficking of ATP-gated P2X1 receptors and human platelet responsiveness.

Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.

Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.

Cystein cathepsin and Hsp90 activities determine the balance between apoptotic and necrotic cell death pathways in caspase-compromised U937 cells.

Results for
""Lactams, Macrocyclic""[mesh_terms]